Re-Evaluating the Effectiveness of Ultrabrief Pulse ECT: The Potential Role of (In)appropriate Seizure Threshold Titration

Why It Matters

If seizure‑threshold titration is optimized, UBP ECT could achieve remission rates comparable to BP ECT, influencing treatment guidelines and research designs for depression therapy.

Key Takeaways

• Meta‑analysis shows ultrabrief pulse ECT underperforms brief pulse in remission
• Authors argue dosing errors from poor seizure‑threshold titration skew results
• Proper titration may close efficacy gap, preserving cognitive safety benefits
• Findings could reshape trial designs and clinical ECT protocols worldwide
• Calls for standardized titration guidelines to optimize ultrabrief ECT outcomes

Pulse Analysis

Electroconvulsive therapy remains a cornerstone for treatment‑resistant depression, but the pulse width used can dramatically affect both efficacy and side‑effects. Ultrabrief pulse (UBP) ECT, defined by pulse durations under 0.5 ms, promises fewer cognitive deficits compared with traditional brief pulse (BP) protocols. However, recent systematic reviews have reported lower remission rates for UBP, casting doubt on its clinical superiority. The correspondence by Meijer and colleagues highlights a critical, often overlooked variable: seizure‑threshold titration. When clinicians set stimulus intensity based on inaccurate thresholds, patients may receive supratherapeutic doses that paradoxically reduce antidepressant response while still preserving the cognitive safety profile of UBP.

The authors draw on a growing body of data linking dose‑response curves to remission outcomes. Studies that meticulously titrate to just‑above seizure threshold consistently show remission rates approaching those of BP ECT, suggesting that the previously observed efficacy gap may be an artifact of dosing practices rather than an inherent limitation of ultrabrief pulses. This insight has immediate implications for clinicians: adopting standardized, patient‑specific titration protocols could unlock the full therapeutic potential of UBP ECT, delivering robust antidepressant effects without the memory impairments historically associated with ECT.

Beyond bedside practice, the argument reshapes the research landscape. Ongoing and future trials of novel antidepressant interventions that use UBP ECT as a comparator must control for titration methodology to avoid confounding results. Regulatory bodies and professional societies may need to issue updated guidelines that codify titration standards, ensuring consistency across sites and studies. In sum, proper seizure‑threshold titration could reconcile the efficacy‑safety trade‑off that has limited UBP adoption, positioning it as a viable, state‑of‑the‑art option for severe depression.